"At Minnesota Oncology, we are dedicated to providing compassionate care for various types of cancer and blood disorders in 12 convenient Twin Cities metro locations as well as several satellite locations. Our mission is to combine the strength of hope with the power of science, one patient at a time."

During the past decade, Minnesota Oncology Hematology, P.A. conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 8 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Minnesota Oncology Hematology, P.A." #1 sponsor was "Pfizer" with 3 trials, followed by "NSABP Foundation Inc" with 2 trials sponsored, "AstraZeneca" with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "Calithera Biosciences, Inc" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Minnesota Oncology Hematology, P.A." #1 collaborator was "Genentech, Inc." with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Cancer International Research Group (CIRG)" with 1 trials as a collaborator and "GOG Foundation" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Minnesota Oncology Hematology, P.A." are "Breast Cancer" (2 trials), "Non-Small Cell Lung Cancer" (2 trials), "Ovarian Cancer" (2 trials), "Advanced Ovarian Cancer" (1 trials) and "Advanced Prostate Cancer" (1 trials). Many other conditions were trialed in "Minnesota Oncology Hematology, P.A." in a lesser frequency.

Most popular intervention types in "Minnesota Oncology Hematology, P.A." are "Drug" (13 trials), "Biological" (2 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "doxorubicin" (3 trials), "Bevacizumab" (2 trials), "Carboplatin" (2 trials) and "Docetaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Minnesota Oncology Hematology, P.A." are 7 trials for "All" genders, 5 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Minnesota Oncology Hematology, P.A.". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Minnesota Oncology Hematology, P.A., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Minnesota Oncology Hematology, P.A., 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".